60

Zhejiang Huakang Pharmaceutical Co Ltd

605077 · SHG · Basic Materials / Chemicals

9.95CNY-0.22 (-2.16%)

Price History

Full chart

Market Stats

Previous Close10.17
Open10.14
Day Range9.92 – 10.17
52-Week Range9.97 – 19.00
Volume2.75M
Market Cap3.49B
P/E (TTM)32.94
Forward P/E0.00
EPS0.35
Dividend Yield4.34%
Beta0.65
50-Day Avg11.33
200-Day Avg14.07

About

Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols and starch sugar worldwide. The company offers polyols products such as xylitol, is a polyol that occurs naturally regular sugar raise blood sugar levels; sorbitol, is produced by the catalytic hydrogenation of D-glucose and is available as a free-flowing crystalline powder, and as aqueous solutions; maltitol a bulk sweetener produced from naturally occurring compounds in corn; erythritol, is produced by the enzymatic hydrolysis of starch into glucose, non-caloric, non-hygroscopic excipient with excellent sweet taste and cooling effect; lactitol is produced by hydrogenation of lactose; mannitol is derived from enzymatic hydrolysis of starch; isomalt is produced from sucrose as a raw material and transformed into isomaltulose by sucrose isomerase. In addition, it offers starch sugar provide high fructose, glucose, maltose syrups, maltodextrin; as well as rare sugar d- xylose, and l-arabinose; and dietary fiber include polydextrose. Zhejiang Huakang Pharmaceutical Co., Ltd. was founded in 2001 and is based in Quzhou, China.

Company Details

  • SectorBasic Materials
  • IndustryChemicals
  • CEOMr. Deshui Chen
  • Employees2.25K
  • Headquarters18 Huagong Road, Quzhou, China, 324302, China
  • Websitehttps://www.huakangpharma.com

Leadership

  • Mr. Deshui ChenChairman of the Board & GM · b. 1969
  • Mr. Jiafa WangFinancial Director · b. 1968
  • Mr. Xinping ChengExecutive Deputy GM & Director · b. 1968
  • Mr. Xiaoyang ZhengDeputy GM & Director · b. 1975
  • Mr. Zhiping WuSecretary · b. 1982

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue763.34M924.63M1.40B1.51B1.32B1.59B2.20B2.78B2.81B4.19B
Growth (%)-+21.13%+51.38%+7.94%-12.66%+20.79%+38.02%+26.48%+0.93%+49.15%
Cost of Revenue600.84M698.04M1.02B999.41M858.18M1.23B1.70B2.11B2.20B3.56B
Gross Profit162.50M226.59M378.53M511.44M461.47M367.13M503.69M671.82M610.82M629.45M
Gross Margin21.29%24.51%27.04%33.85%34.97%23.03%22.89%24.14%21.75%15.03%
Operating Expense131.39M163.79M154.23M200.91M105.36M110.49M154.46M244.73M321.47M306.18M
Operating Income31.11M62.80M224.31M310.53M356.11M256.64M349.23M427.09M289.34M323.27M
Operating Margin4.08%6.79%16.02%20.55%26.99%16.10%15.87%15.35%10.30%7.72%
EBITDA98.40M124.65M294.46M373.50M417.40M342.37M463.16M633.26M520.38M619.56M
EBITDA Margin12.89%13.48%21.04%24.72%31.63%21.48%21.05%22.76%18.53%14.79%
Net Income28.71M55.94M199.38M270.11M307.17M236.71M319.28M371.45M268.48M200.30M
Net Income Margin3.76%6.05%14.24%17.88%23.28%14.85%14.51%13.35%9.56%4.78%
R&D21.65M28.12M43.92M53.79M65.03M84.23M99.71M124.28M128.41M144.92M
R&D as % of Total Revenue2.84%3.04%3.14%3.56%4.93%5.28%4.53%4.47%4.57%3.46%
Interest Expense19.97M20.01M21.22M13.84M8.80M4.33M14.93M38.01M34.51M101.40M
Interest Expense % of Total Revenue2.62%2.16%1.52%0.92%0.67%0.27%0.68%1.37%1.23%2.42%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets682.12M702.16M1.05B1.15B1.43B3.00B3.91B6.18B6.99B8.04B
Total Liabilities546.03M514.17M607.22M469.20M490.16M569.56M1.25B3.08B3.74B4.79B
Total Equity135.88M187.80M440.92M684.81M939.52M2.43B2.66B3.09B3.24B3.24B
Cash61.93M68.58M184.31M175.21M248.78M1.24B1.04B2.13B434.21M1.16B
Total Debt278.51M241.56M279.07M168.33M165.94M142.11M667.18M2.42B2.01B-
Net Debt216.58M172.98M94.76M-6.88M-82.85M-1.10B-373.24M292.65M1.58B1.66B

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow93.02M80.56M140.97M281.31M335.24M264.32M271.98M619.47M146.50M424.40M
Investing Cash Flow-48.59M-28.12M-116.58M-86.33M-348.48M-1.25B63.92M-1.31B-1.59B-
Financing Cash Flow-43.50M-43.13M62.69M-165.29M-63.78M1.22B391.88M1.74B-310.54M-
Capital Expenditure25.32M16.49M121.38M132.21M252.95M360.93M539.75M690.70M1.43B483.38M
Free Cash Flow67.69M64.07M19.60M149.10M82.29M-96.61M-267.77M-71.23M-1.28B-58.98M
Dividends Paid22.83M23.46M46.49M26.23M52.45M116.56M97.91M173.09M196.56M253.47M
FCF to OCF72.78%79.53%13.90%53.00%24.55%-36.55%-98.45%-11.50%-875.91%-13.90%
Dividend Paid to FCF33.73%36.61%237.26%17.59%63.74%-120.66%-36.56%-243.02%-15.32%-429.76%

Earnings

Report DateMar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Apr 28, 2022Aug 12, 2022Oct 26, 2022Mar 23, 2023Apr 27, 2023
EPS Estimate---------
EPS Actual0.230.280.300.230.220.400.490.290.39
Surprise---------
Timing----Pre-marketPre-marketPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap3.49B
Enterprise Value5.98B
Trailing P/E32.94
Forward P/E0.00
Price / Sales0.73
Price / Book1.13
EPS0.35
Book Value10.55
Revenue (TTM)4.80B
Gross Profit (TTM)566.30M
EBITDA563.71M
Profit Margin2.26%
Operating Margin4.32%
Return on Equity3.43%
Return on Assets1.84%
Shares Outstanding302.70M
Shares Float154.11M
Beta0.65
Dividend Yield4.34%
Dividend Rate0.50
Payout Ratio142.86%

Dividends

20261×
0.30Jun 17, 2026
20252×
0.20Sep 29, 20250.50Apr 24, 2025
20241×
0.70May 28, 2024
20231×
0.46Apr 28, 2023
20221×
0.46May 26, 2022
20211×
0.39May 19, 2021

Stock Splits

  • May 28, 20241.3:1
  • May 26, 20221.4:1
  • May 19, 20211.4:1